ASP Isotopes Inc. reported a net loss of $159.8 million for the year ended December 31, 2025, compared to a net loss of $32.4 million for the previous year. The company's revenue increased significantly to $23.8 million, up from $4.1 million in 2024. This increase in revenue is primarily attributed to $18.2 million in construction service revenue from the Skyline acquisition and $5.6 million from the sale of nuclear medical doses for PET scanning. Cost of revenue also increased substantially, reaching $20.4 million in 2025 compared to $2.5 million in 2024.

Operating expenses for ASP Isotopes Inc. rose to $63.3 million in 2025, a considerable increase from $28.0 million in 2024. This included $2.7 million in acquired in-process research and development, $12.4 million in research and development expenses, and $48.2 million in selling, general, and administrative expenses. The increase in research and development expenses was primarily due to increased personnel-related costs, manufacturing engineering testing expenses, and facility and depreciation expenses. The increase in selling, general, and administrative expenses was primarily due to increased personnel-related costs and professional fees.

Strategic developments for ASP Isotopes Inc. in 2025 included the acquisition of a controlling interest in Skyline Builders Group Holding Ltd. and investments in early-stage drug development companies such as IsoBio. The company also progressed its uranium enrichment initiative, entering into a Loan Agreement and supply agreements with TerraPower, LLC. Key operational developments included the commencement of commercial production of enriched isotopes at ASP enrichment facilities in Pretoria, South Africa, and the completion of the commissioning phase for highly enriched Yb-176 at its QE technology facility.

As of December 31, 2025, ASP Isotopes Inc. employed 271 people on a full-time basis. The company's outlook includes targeting initial commercial shipments of enriched C-14 in mid-2026 and enriched Si-28 during the second quarter of 2026, as well as Yb-176 in mid-2026 or the third quarter of 2026. The company also plans to continue research and development for the enrichment of uranium to demonstrate its capability to produce HALEU using QE technology. The company believes its existing cash and cash equivalents, proceeds from short-term investments, cash flow from operations, and conditionally approved senior secured debt facilities will be sufficient to fund its operations for at least the next 12 months.

About ASP Isotopes Inc.

ASP Isotopes Inc. is an advanced materials company specializing in isotope enrichment technologies, focusing on Carbon-14, Silicon-28, and Ytterbium-176. With a significant market opportunity in healthcare, technology, and energy, ASP targets industries requiring high-value isotopes. The company is expanding its operations in South Africa and exploring uranium enrichment for nuclear fuels. Strategic partnerships and innovative technologies position ASP to address critical supply chain challenges in isotope production.

This description was generated via AI from an annual report. Updated 10 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.